Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Diagnostics (Basel) ; 13(7)2023 Mar 30.
Article in English | MEDLINE | ID: mdl-37046521

ABSTRACT

Radiomics is a discipline that involves studying medical images through their digital data. Using "artificial intelligence" algorithms, radiomics utilizes quantitative and high-throughput analysis of an image's textural richness to obtain relevant information for clinicians, from diagnosis assistance to therapeutic guidance. Exploitation of these data could allow for a more detailed characterization of each phenotype, for each patient, making radiomics a new biomarker of interest, highly promising in the era of precision medicine. Moreover, radiomics is non-invasive, cost-effective, and easily reproducible in time. In the field of oncology, it performs an analysis of the entire tumor, which is impossible with a single biopsy but is essential for understanding the tumor's heterogeneity and is known to be closely related to prognosis. However, current results are sometimes less accurate than expected and often require the addition of non-radiomics data to create a performing model. To highlight the strengths and weaknesses of this new technology, we take the example of hepatocellular carcinoma and show how radiomics could facilitate its diagnosis in difficult cases, predict certain histological features, and estimate treatment response, whether medical or surgical.

2.
Clin Nucl Med ; 46(10): 797-806, 2021 Oct 01.
Article in English | MEDLINE | ID: mdl-34238796

ABSTRACT

PURPOSE: The aim of the study was to evaluate the clinical utility of pretreatment 18F-FDG PET/CT with quantitative evaluation of peritoneal metabolic cartography in relation to staging laparoscopy for ovarian carcinomatosis. PATIENTS AND METHODS: A retrospective review of prospectively collected data from 84 patients with FIGO (International Federation of Gynecology and Obstetrics) stage IIIC to IV ovarian cancer was carried out. All patients had a double-blinded 18F-FDG PET/CT review. Discriminant capacity of metabolic parameters to identify peritoneal carcinomatosis in the 13 abdominal regions according to the peritoneal cancer index was estimated with area under the receiver operating characteristic curve (AUC). RESULTS: The metabolic parameter showing the best trade-off between sensitivity and specificity to predict peritoneal extension compared with peritoneal cancer index score was the metabolic tumor volume (MTV), with a Spearman ρ equal to 0.380 (P < 0.001). The AUC of MTV to diagnose peritoneal involvement in the upper abdomen (regions 1, 2, and 3) ranged from 0.740 to 0.765. MTV AUC values were lower in the small bowel regions (9-12), ranging from 0.591 to 0.681, and decreased to 0.487 in the pelvic region 6. 18F-FDG PET/CT also improved the detection of extra-abdominal disease, upstaging 35 patients (41.6%) from stage IIIC to IV compared with CT alone and leading to treatment modification in more than one third of patients. CONCLUSIONS: 18F-FDG PET/CT metrics are highly accurate to reflect peritoneal tumor burden, with variable diagnostic value depending on the anatomic region. MTV is the most representative metabolic parameter to assess peritoneal tumor extension.


Subject(s)
Ovarian Neoplasms , Peritoneal Neoplasms , Female , Fluorodeoxyglucose F18 , Humans , Ovarian Neoplasms/diagnostic imaging , Peritoneal Neoplasms/diagnostic imaging , Positron Emission Tomography Computed Tomography , Radiopharmaceuticals , Retrospective Studies , Tomography, X-Ray Computed , Tumor Burden
3.
Q J Nucl Med Mol Imaging ; 64(3): 307-312, 2020 Sep.
Article in English | MEDLINE | ID: mdl-30792379

ABSTRACT

BACKGROUND: Radiolabeled white blood cells (WBCs) prepared in radiopharmacies are used to detect infectious or inflammatory sites with scintigraphy. Radiolabeling can be performed by using a disposable closed device, Leukokit®. Nevertheless, owing to the high radiosensitivity of lymphocytes, the question of eliminating lymphocytes before granulocyte radiolabeling is still a controversial step. The aim of this study was to assess a new modified Leukokit® with a protocol that allows granulocyte radiolabeling only. METHODS: Seventy patients (male/female: 40/30, mean age: 61 years) with suspected infectious diseases underwent labeled leukocyte scintigraphy by radiolabeling with a density gradient medium in addition to Leukokit®. Compliance and quality of radiolabeling were checked according to the following criteria: visual inspection, labeling efficiency, cell viability (Trypan blue exclusion test), cell subset recovery test, lymphocyte elimination rate (granulocyte/WBC rate) and sterility test using media fills. RESULTS: Visual inspection showed that all cell preparations were free of residual cell clumps or fibrin clots. Mean labeling efficiency was 70.4±9.4% compliant with EANM Guidelines for leukocyte labeling. The mean cell viability was 97.7±1.4% (>96%). The mean number of leucocytes injected was 116x106 ±62x106 (>50x106). The mean erythrocyte/WBC ratio was 2.1 ±0.9 (<3) and the removed lymphocyte rate was 97.4±1.6% (>90%). Finally, the three sterility tests were negative and therefore successful. CONCLUSIONS: Purification of granulocytes with Leukokit® can safely, easily and effectively be performed using a density gradient medium. Moreover, clarification regarding the status of density gradient medium could provide support for its clinical use even if further studies are needed. Since all technical obstacles have been removed, the precautionary principle should apply and lead users to eliminate lymphocytes that are highly radiosensitive cells and whose in vivo fate is uncertain.


Subject(s)
Granulocytes/metabolism , Isotope Labeling/methods , Cell Survival , Female , Granulocytes/cytology , Humans , Isotope Labeling/instrumentation , Male , Middle Aged , Quality Control
4.
Eur Radiol ; 29(12): 6708-6716, 2019 Dec.
Article in English | MEDLINE | ID: mdl-31250167

ABSTRACT

OBJECTIVE: To study a muscle-to-muscle standardised uptake value (SUV) ratio with FDG-PET/CT (FDG-PET) as a marker for the detection of disease activity in dermatomyositis (DM). METHODS: Patients with DM (n = 24) who met the European Neuro-Muscular Centre diagnostic criteria were retrospectively identified over a 3-year period through a national survey. Muscle biopsy was performed in all patients. Maximum SUV was measured in proximal muscles (SUVPROX) that had the highest radiotracer uptake on visual grading as well as in the musculus longissimus thoracis (SUVMLT), whereas mean SUV was measured for the liver (SUVLIV). Muscle-to-liver SUV ratios for either muscle group were compared and a SUVPROX/SUVMLT ratio was calculated. SUVPROX/SUVMLT of DM patients were compared with age- and sex-matched control subjects (n = 24) with melanoma who had received FDG-PET scans. RESULTS: DM patients presented with proximal and symmetrical muscle uptake. Differences in SUVPROX/SUVLIV and SUVMLT/SUVLIV ratios in DM subjects were significant (p < 0.001). SUVPROX/SUVMLT ratios in DM and their controls also differed significantly (p = 0.0012). The SUVPROX/SUVMLT ratio threshold between DM subjects and controls was 1.73 with a sensitivity of 50% (CI95%, 29.1 to 70.9%) and specificity at 83.3% (CI95%, 62.6 to 95.3%). When amyopathic DM patients were removed from the analysis, specificity was increased to 95% (CI95%, 75.1 to 99.9%) with a likelihood ratio of 10 and an AUC of 83.4% (CI95%, 71.4 to 95.4%). CONCLUSION: A muscle-to-muscle SUVPROX/SUVMLT ratio with a cut-off value of 1.73 in FDG-PET imaging might serve as a non-invasive marker to determine disease activity in dermatomyositis. KEY POINTS: • [18F]-FDG PET-scanner standardised uptake value (SUV) could reflect disease activity in dermatomyositis (DM). • A ratio of SUV in proximal muscles (SUVPROX) to SUV in musculus longissimus thoracis (SUVMLT) could be used to determine active DM. • Active disease is suspected for SUV PROX /SUV MLT ratios greater than 1.73.


Subject(s)
Dermatomyositis/diagnostic imaging , Fluorodeoxyglucose F18/pharmacokinetics , Muscle, Skeletal/diagnostic imaging , Positron Emission Tomography Computed Tomography/methods , Radiopharmaceuticals/pharmacokinetics , Adult , Aged , Aged, 80 and over , Dermatomyositis/metabolism , Dermatomyositis/pathology , Female , Humans , Male , Middle Aged , Muscle, Skeletal/metabolism , Muscle, Skeletal/pathology , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity
6.
Medicine (Baltimore) ; 96(22): e6889, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28562539

ABSTRACT

RATIONALE: Exogenous lipoid pneumonia is a rare condition due to abnormal presence of oily substances in the lungs. It is a rarely known cause for false positive FDG PET-CT results and can sometimes lead to invasive investigations. Searching and finding the source of the oily substance is one of the keys to the diagnosis. Inhalation of oily drugs during snorting has rarely been described. PATIENT CONCERNS: A patient with well controlled HIV infection was referred for an FDG PET-CT to assess extension of Kaposi's disease, recently removed from his right foot. The patient had no particular symptoms. DIAGNOSES: Abnormal uptake of FDG was found in a suspicious lung nodule. An experienced radiologist thought the nodule was due to lipoid pneumonia. INTERVENTIONS: Bronchoalveolar lavage fluid did not contain lipid-laden macrophages but bronchoscopy showed violet lesions resembling Kaposi's disease lesions. Lobectomy was performed after a multidisciplinary discussion. OUTCOMES: Anatomopathological analysis revealed the nodule was due to lipoid pneumonia. The patient's quality of life did not diminish after the operation and he is still in good health. The source of the oily substance causing lipoid pneumonia was found after the surgery: the patient used to snort oily drugs. LESSONS: The presence of a suspicious lung nodule possibly due to lipoid pneumonia in a patient with known Kaposi's disease was difficult to untangle and lead to invasive surgery. It is possible that if a source of exogenous lipoid pneumonia had been found beforehand, surgery could have been prevented.


Subject(s)
Lung/diagnostic imaging , Oils, Volatile/adverse effects , Pneumonia, Lipid/diagnostic imaging , Pneumonia, Lipid/etiology , Positron Emission Tomography Computed Tomography , Substance-Related Disorders/complications , False Positive Reactions , Fluorodeoxyglucose F18 , HIV Infections/complications , HIV Infections/diagnostic imaging , Humans , Inhalation Exposure/adverse effects , Lung/pathology , Lung/surgery , Male , Middle Aged , Oils, Volatile/administration & dosage , Pneumonia, Lipid/pathology , Pneumonia, Lipid/surgery , Radiopharmaceuticals , Sarcoma, Kaposi/complications , Sarcoma, Kaposi/diagnostic imaging , Substance-Related Disorders/diagnostic imaging , Substance-Related Disorders/pathology , Substance-Related Disorders/surgery
7.
J Alzheimers Dis ; 34(1): 315-23, 2013.
Article in English | MEDLINE | ID: mdl-23168448

ABSTRACT

Recent studies have suggested that memory circuits can be modulated by deep brain stimulation (DBS). This propriety might be used to slow down cognitive decline in patients suffering from Alzheimer's disease (AD). We conducted a prospective study to evaluate the feasibility and safety of DBS in AD patients with mild cognitive decline. Inclusion criteria were: patients (<70 years old) with AD diagnosed for less than 2 years, predominant impairment of episodic memory, and Mini-Mental Status Exam (MMSE) score between 20 and 24. The fornix was stimulated bilaterally by electrodes implanted stereotactically in the hypothalamus. Clinical, biological, neuropsychological, and imaging evaluations were conducted 3 months before surgery and 3, 6, and 12 months thereafter. During the one year-period of inclusion, 110 patients with recently diagnosed AD and predominant impairment of episodic memory were screened. Only 9 patients (8.2%) fulfilled all the inclusion criteria. Finally, just one patient accepted to be operated (acceptance rate 11.1%) and completed the study. No complications occurred and the stimulation was perfectly tolerated. After one year of stimulation, the memory scores (MMSE, ADAS-Cog, Free and Cued Selective Reminding Test) were stabilized compared to baseline, and mesial temporal lobes metabolism increased. This pilot study provides new data about the safety of fornix DBS in the hypothalamus. However, it suggests that only a small proportion of AD patients might be interested in this approach and that the acceptance of DBS by AD patients was low, raising questions about the relevance of this approach to meet the expectations of these patients.


Subject(s)
Alzheimer Disease/complications , Brain/physiology , Deep Brain Stimulation/methods , Memory Disorders/etiology , Memory Disorders/therapy , Adult , Alzheimer Disease/diagnosis , Feasibility Studies , Female , Fluorodeoxyglucose F18 , Follow-Up Studies , Humans , Magnetic Resonance Imaging , Male , Memory Disorders/diagnosis , Mental Status Schedule , Middle Aged , Neuropsychological Tests , Pilot Projects , Positron-Emission Tomography , Time Factors , Young Adult
8.
Bull Cancer ; 95(11): 1083-7, 2008 Nov.
Article in French | MEDLINE | ID: mdl-19036681

ABSTRACT

The purpose of the present study was to retrospectively evaluate the nature and significance of unexpected focal 18-FDG uptake localized by PET/CT within the intestinal tract. Methods. The data of 4,033 PET/CT were retrospectively reviewed. One hundred and eighty PET/CT showed unexpected focal uptakes (patients with known intestinal neoplasia were excluded). Among them, 42 patients corresponding to 47 focal uptake sites were investigated by endoscopy or surgery. Results. Height endoscopy results were negative (17%). We found 25 adenomatous polyps (53.2%), 10 neoplasms (21.3%) and 4 inflammatory lesions (8.5%). 18-FDG uptake values were not statistically different between the 4 groups. Conclusion. Eighty-three percent of unexpected intestinal foci of hypermetabolism are either inflammatory, malignant or premalignant lesions. These results justify systematic investigation of these lesions.


Subject(s)
Fluorodeoxyglucose F18/pharmacokinetics , Intestinal Mucosa/metabolism , Intestinal Neoplasms/diagnostic imaging , Precancerous Conditions/metabolism , Radiopharmaceuticals/pharmacokinetics , Adult , Aged , Aged, 80 and over , Colonic Neoplasms/diagnostic imaging , Colonic Neoplasms/metabolism , Female , Humans , Incidental Findings , Intestinal Neoplasms/metabolism , Intestinal Polyps/diagnostic imaging , Intestinal Polyps/metabolism , Intestines/diagnostic imaging , Male , Middle Aged , Positron-Emission Tomography/methods , Precancerous Conditions/diagnostic imaging , Rectal Neoplasms/diagnostic imaging , Rectal Neoplasms/metabolism , Retrospective Studies , Sigmoid Neoplasms/diagnostic imaging , Sigmoid Neoplasms/metabolism , Tomography, Emission-Computed , Tomography, X-Ray Computed/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...